3-Phenyl-3-hydroxy-1-methyl-piperidin | 6755-55-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-Phenyl-3-hydroxy-1-methyl-piperidin
• 英文别名: 1-Methyl-3-phenylpiperidin-3-ol
• CAS: 6755-55-1
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: DMRIFTWXBIVQLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-甲基哌啶-3-酮 、 phenylmagnesium bromide 在 乙醚 、 苯 作用下， 生成 3-Phenyl-3-hydroxy-1-methyl-piperidin
  参考文献：
  名称：

  A consistent and verifiable macroscopic model for the dissolution of liquid CO2 in water under hydrate forming conditions

  摘要：

  Direct injection of liquid CO2 into the ocean has been proposed as one method to reduce the emission levels Of CO2 into the atmosphere. When liquid CO2 is injected (normally as droplets) at ocean depths > 500 in, a solid interfacial region between the CO2 and the water is observed to form. This region consists of hydrate clathrates and hinders the rate of dissolution Of CO2 . It is, therefore, expected to have a significant impact on the injection of liquid CO2 into the ocean. Up until now, no consistent and predictive model for the shrinking of droplets Of CO2 under hydrate forming conditions has been proposed. This is because all models proposed to date have had too many unknowns. By computing rates of the physical and chemical processes in hydrates. via molecular dynamics simulations, we have been able to determine independently some of these unknowns. We then propose the,most reasonable model and use it to make independent predictions of the rates of mass transfer and thickness of the hydrate region. These predictions are compared to measurements, and implications to the rates of shrinkage Of CO2 droplets under varying flow conditions are discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0196-8904(01)00184-4

文献信息

• [EN] THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES DE PYRIDAZINE ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016138114A1

  公开（公告）日：2016-09-01

  The present invention relates to compounds of formula (I): (I) and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.

  本发明涉及式(I)的化合物及其盐，其中：R1-R4具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作BRG1、BRM和/或PB1的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种BRG1介导的疾病、BRM介导的疾病和/或PB1介导的疾病中使用这些化合物和盐的方法。
• BALSAMO A.; LAPUCCI A.; MACCHIA B.; MACCHIA F.; CESERANI R.; LONGIAVE D., EUR. J. MED. CHEM.-CHIM. THER., 1981, 16, NO 2, 163-169
  作者：BALSAMO A.、 LAPUCCI A.、 MACCHIA B.、 MACCHIA F.、 CESERANI R.、 LONGIAVE D.

  DOI：——

  日期：——
• COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER
  申请人：ARGONAUT THERAPEUTICS LIMITED

  公开号：US20200325128A1

  公开（公告）日：2020-10-15

  The present disclosure relates to compounds suitable for the inhibition of protein arginine methyl-transferase (PRMT), in particular PRMT5. These compounds may be for use as therapeutic agents, in particular, agents for use in the treatment and/or prevention of proliferative diseases, such as cancer.
• US8247401B2
  申请人：——

  公开号：US8247401B2

  公开（公告）日：2012-08-21